3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Thyroid Carcinoma, Anaplastic
4
Thyroid Neoplasms
3
Neuroendocrine Tumors
3
Neoplasms
3
Head and Neck Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
Temozolomide
11
Cyclophosphamide
11
Radiotherapy
7
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Cisplatin
6
Vincristine
5
Etoposide
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
sargramostim
3
Thiotepa
3
Melphalan
3
Carmustine
3
Automobiles
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
gallium Ga 68 dotatate
2
fludarabine
2
dactolisib
2
aldesleukin
2
Thalidomide
2
TH 302
2
Paclitaxel
2
Irinotecan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Everolimus
2
Donepezil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroectodermal Tumors, Primitive
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts